Beyond symptom control: Redefining IMID care in Malaysia

The future of IMID management will likely be shaped by advances in biologics, personalised medicine, and digital health. 

Medical innovation was for many years focused on improved survival and symptom relief. Today, however, we are seeing the impact of innovation far beyond disease control, innovation is increasingly shaping prevention, preservation of long-term function, and quality of life.  

This shift is especially evident in the management of immune-mediated inflammatory diseases (IMIDs), including chronic conditions such as Crohn’s disease, ulcerative colitis, psoriasis, and rheumatoid arthritis, which affect millions globally and require lifelong care.

Over the past two decades, biologic therapies have played a central role in this transformation. By targeting specific immune pathways responsible for inflammation, these treatments have enabled more precise disease control and significantly improved clinical outcomes. Rather than simply reducing symptoms or flare frequency, clinicians are now able to aim for sustained remission, helping to prevent irreversible tissue damage and preserve organ integrity over time.

Historically, IMID management focused primarily on controlling symptoms and reducing the frequency of flares. Conventional therapies, while beneficial, often did not fully prevent disease progression or long-term complications. This meant many patients experienced cumulative tissue damage, disability, and diminished quality of life despite ongoing treatment.

Today, clinicians are increasingly adopting treat-to-target (T2T) approaches supported by biologic innovation. The goal is no longer limited to symptom suppression, but to achieving sustained remission and preventing long-term complications. This shift is transforming patient outcomes across a range of IMIDs.

In psoriasis, early intervention with newer biologics such as IL-23 inhibitors has demonstrated that it can alter the natural history of plaque psoriasis, potentially promising drug-free remission for patients, rather than just managing symptoms. These therapies have enabled many patients to achieve levels of skin clearance that are unattainable with conventional systemic treatments.

Treatments for IBD have similarly shifted toward achieving mucosal healing, sustained remission and prevention of complications such as strictures and hospitalisation. Biologic therapies targeting inflammatory pathways, including anti-TNF agents and newer biologics, have demonstrated improved clinical outcomes and reduced disease progression.

Similarly, in rheumatology, early intervention with biologics and targeted disease-modifying therapies have transformed the management of RA, enabling better control of inflammation and significantly reducing the risk of degeneration of the joints and long-term disability. Early, aggressive treatment strategies combined with biologic disease-modifying antirheumatic drugs (bDMARDs) have made disease remission a realistic target for patients with early RA.

These advances are not only clinically meaningful but also transformative for patients’ daily lives. Effective disease control allows individuals to maintain employment, participate in family and social activities, and experience an improved overall quality of life.

Innovation remains central to this progress. Biologic research continues to expand treatment possibilities for patients who previously had limited options or inadequate response to existing therapies. Advances in immunology are allowing clinicians to tailor treatments more effectively and intervene earlier in the disease course. For patients in Malaysia, these advances represent more than clinical outcomes or reduced long-term complications; they offer the possibility of maintaining employment and participating more fully in family and social life.

Looking ahead, the future of IMID management in Malaysia will likely be shaped by continued advances in biologics, personalised medicine, and digital health integration. Innovations such as biomarker-guided treatment selection, therapeutic drug monitoring, and emerging therapeutic platforms are expected to further refine disease management and improve patient outcomes.

However, innovation alone cannot improve patient outcomes without timely access to treatment. In Malaysia, barriers include reimbursement limitations within the public sector, varying levels of insurance coverage, and uneven distribution of specialist care between urban and rural areas. As a result, many patients face significant challenges in securing funding for advanced therapies. Addressing these barriers will require coordinated efforts across healthcare stakeholders.

Healthcare transformation is a shared responsibility. Collaboration among policymakers, healthcare providers, industry partners, and patient advocacy groups (PAGs) can strengthen health technology assessment (HTA) frameworks, improve education amongst clinicians, and facilitate earlier diagnosis and initiation of treatments, ultimately enabling patients to receive timely access to effective therapies.

This shift in treatment approach comes at a critical time. Across Southeast Asia, IMIDs are becoming more prevalent due to rapid urbanisation, dietary transitions, environmental exposures, and improved diagnostic capabilities. The rising incidence of inflammatory bowel disease (IBD) and rheumatologic conditions now mirrors Western epidemiological patterns from 50 years ago. Studies also show that psoriasis imposes a large burden on the Asia Pacific, with prevalence in adults ranging from 0.14% in East Asia to about 2% in Australasia, although epidemiological data for this region is still lacking.

In Malaysia, IBD remains underdiagnosed, with a mean incidence of 0.69 per 100,000 population as of 2022. However, hospital-based studies show a steady increase in incidence from 0.36 between 1980 and 1989 to 0.69 between 2010 and 2018. RA affects approximately five in 1,000 people in Malaysia, with a prevalence of around 0.5% according to the National Rheumatoid Arthritis Registry, or tens of thousands of patients requiring long-term care.

A study conducted in Johor in 2020 found that the incidence of psoriasis remained relatively stable between 2010 and 2017 (around 30 new cases per 100 000 person‐years), and then increased from 2018 onwards, reaching a rate of 60·9 per 100 000 people‐years in 2020.

Chronic inflammatory diseases are associated with recurrent hospital visits, long-term medication use, and a reduced capacity to work. These factors contribute to increased utilisation of healthcare resources and a loss of productivity, underscoring the importance of effective disease control and early intervention.

Ultimately, raising treatment expectations for IMIDs is about redefining what patients can achieve whilst living with chronic inflammatory diseases. By moving beyond reactive symptom control toward proactive disease prevention and management, healthcare systems can empower patients to lead fuller, more productive lives.